Figure S2. The role of hepatic PPARγ in T0901317 induced time-dependent effects on VLDL-TG metabolism. A) Hepatic Pparγ2 gene expression in C57BL/6J mice. B) Hepatic Pparγ1 gene expression in C57BL/6J mice. C) Hepatic Pparγ2 gene expression in Lxrα−/− mice and their wildtype littermates. D) Representative blots for hepatic PPARγ protein expression in C57BL/6J mice, and signal quantification results from 6 independent individuals normalized for actin protein expression; expressed in arbitrary units (AU). E) Hepatic Fabp4 and Ucp2 gene expression in C57BL/6J mice. F) Lipoprotein profiles in Pparγ hep−/− mice and their wild-type littermates. G) Hepatic mRNA expression of genes involved in VLDL-TG metabolism and Pparγ in Pparγ hep−/− mice and their wild-type littermates. Mice were treated with T0901317 for the indicated time periods. Values represent means ± SEM for n=6-8 mice per group; * p<0.05; ** p<0.01; *** p<0.001 vs. untreated controls and # p<0.05; ## p<0.01; ### p<0.001 day 7 vs. day 1 or day 14 vs. day 7 or vs. same treatment in other genotype (Conover test). Fabp4 = fatty acid binding protein 4, Ucp2 = uncoupling protein 2, Lpl = lipoprotein lipase; Pparγ = peroxisome proliferator-activated receptor γ; Pltp = phospholipid transfer protein; Vldlr = very low density lipoprotein receptor.